Clinical trials
for patients

The main goal of this study is to determine whether ZIM alone or in combination with DOM and chemotherapy is safe and effective when given to patients with the type of cancer you have. The first standard treatment approved for metastatic NSCLC without gene alterations is anti-PD-(L)1 immunotherapy, which is a drug that helps the immune system target cancer cells for destruction, combined with or without platinum-based chemotherapy. The study will also attempt to understand how the combination of...

The purpose of this clinical trial is to determine whether an investigational drug called TEV-56286 (also known as ANLE138b) can stabilize, limit, or slow the worsening of AMS symptoms, and to determine the safety and tolerability of this drug in adults with AMS, compared to placebo.

The aim of this study is to determine the efficacy and safety of the investigational drug AB8939 in patients with relapsed or refractory acute myeloid leukemia or refractory myelodysplastic syndrome.

The aim of this study is to determine the most appropriate dose of BI 764532 that patients with cancer like yours who have progressed after treatment with available standard therapies, including platinum therapy, or who are not eligible for available standard therapies, will receive in the future. Only patients confirmed to be positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study.

The main objective of this study is to investigate the efficacy and safety profile of MIRV with an alternative administration schedule to the approved U.S. schedule, with the aim of potentially improving the risk-benefit profile. In addition, a starting dose of MIRV will be determined in patients with moderate hepatic impairment.